SCHEMBL31292095

SCHEMBL31292095

CC(C)(C(=O)O)N1Cc2ccccc2C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.50
RIPK1 Q13546 4/20 0.45
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HSD17B3 P37058 1/20 0.42
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSP90AA1 P07900 4/20 0.41
HSP90AB1 P08238 3/20 0.41
KDM4E B2RXH2 1/20 0.41
HSP90B1 P14625 1/20 0.40
NLRP3 Q96P20 1/20 0.40
NAMPT P43490 2/20 0.39
KCNH2 Q12809 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31292601 0.79 NOTUM (0.46) NOTUMRIPK1NPC1RAB9AMEN1
Trifluoroacetic Acid SCHEMBL31197675 0.78 NOTUM (0.42) NOTUMRIPK1NPC1RAB9AHSD17B3
SCHEMBL1387873 0.75 RIPK1 (0.37) RIPK1NPC1RAB9AMEN1KMT2A
SCHEMBL861946 0.75 MAOA (0.44) NOTUMRIPK1NPC1RAB9AMEN1
SCHEMBL24606352 0.71 MAOA (0.41) NOTUMRIPK1NPC1RAB9AMEN1
SCHEMBL12935926 0.71 RIPK1 (0.72) NOTUMRIPK1MEN1KMT2AHSP90AA1
SCHEMBL4220548 0.70 DPP8 (0.40) NOTUMRIPK1NPC1RAB9AHSP90AA1
SCHEMBL20078475 0.69 MAOA (0.55) NOTUMRIPK1NPC1RAB9AMEN1
SCHEMBL28677772 0.69 NOTUM (0.43) NOTUMRIPK1NPC1RAB9AMEN1
SCHEMBL29758685 0.69 NOTUM (0.64) NOTUMNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340528-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-11-06 US disclosed
US-12459920-B2 Targeted protein degradation MONTE ROSA THERAPEUTICS AG (CH) 2025-11-04 US disclosed
US-20250243180-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-07-31 US disclosed
WO-2025024521-A1 SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS, INC. (US) 2025-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243180-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 NOTUM 4311/4885RIPK1 3/4885NPC1 654/4885
US-12459920-B2 Targeted protein degradation NEK7, NEK1, RIPK1 NOTUM 4311/4885RIPK1 3/4885NPC1 662/4885
US-20250340528-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 NOTUM 4311/4885RIPK1 3/4885NPC1 654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.